Role of the Kidney in Hypertension

Comprehensive Hypertension

Volumn , Issue , 2007, Pages 241-263

  Granger, Joey P ^a   Hall, John E ^b,c  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b Department of Physiology and Biophysics   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882831302     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03961-1.50026-X     Document Type: Chapter

References (143)

1. AC Guyton (1980) Arterial pressure and hypertension. Circulatory Physiology II Philadelphia: W.B. Saunders
2. JE Hall, HL Mizelle, DA Hildebrandt and MW Brands (1990) Abnormal pressure natriuresis: a cause or a consequence of hypertension? Hypertension 15 547-559.
3. JE Hall, AC Guyton and MW Brands (1996) Pressure-volume regulation in hypertension. Kidney Int 49(Suppl 55), S35-S41.
4. AC Guyton (1991) Abnormal renal function and autoregulation in essential hypertension. Hypertension 18(Suppl 5), III49-III53.
5. JE Hall (1991) Renal function in one-kidney one-clip hypertension and low renin essential hypertension. Am J Hypertens 4 523S-533S.
6. H Goldblatt, J Lynch, RF Hanzal and WW Summerville (1934) Studies on experimental hypertension. I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 59 347-380.
7. G Kimura and BM Brenner (1995) The renal basis for salt sensitivity in hypertension. JH Laragh, BM Brenner (Eds) Hypertension: Pathophysiology, Diagnosis, and Management New York: Raven Press 1569-1588.
8. JH Laragh (1989) Nephron heterogeneity: clue to the pathogenesis of essential hypertension and effectiveness of angiotensin-converting enzyme inhibitor treatment. Am J Med 87 2S-14S.
9. BM Brenner (1985) Nephron adaptation to renal injury or ablation. Am J Physiol 249 F324-F337.
10. RA Norman Jr, PG Galloway, DJ Dzielak and M Huang (1988) Mechanisms of partial renal infarct hypertension. J Hypertens 6 397-403.
11. JB Langston, AC Guyton, BH Douglas and PE Dorsett (1963) Effect of changes in salt intake on arterial pressure and renal function in partially nephrectomized dogs. Circulation Res 12 508-512.
12. JE Hall, MW Brands and EW Shek (1996) Central role of the kidney and abnormal fluid volume control in hypertension. J Hum Hypertens 10 633-639.
13. MH Weinberger (1996) Salt sensitivity of blood pressure in humans. Hypertension 27 481-490.
14. RJ Johnson, B Rodriguez-Iturbe, T Nakagawa, et al. (2005) Subtle renal injury is likely a common mechanism for salt-sensitive essential hypertension. Hypertension 45 326-330.
15. RP Lifton (1996) Molecular genetics of human blood pressure variation. Science 272 676-680.
16. MS Dunhill and W Halley (1973) Some observations on the quantitative anatomy of the kidney. J Pathol 110 113-161.
17. JE Hall, TG Coleman and AC Guyton (1989) The renin-angiotensin system: normal physiology and changes in older hypertensives. J Am Geriatric Soc 37 801-813.
18. JE Hall (1986) Control of sodium excretion by angiotensin II: intrarenal mechanisms and blood pressure regulation. Am J Physiol 250 R960-R972.
19. JE Hall, AC Guyton, MJ Smith Jr and TG Coleman (1980) Blood pressure and renal function during chronic changes in sodium intake: role of angiotensin. Am J Physiol 239 F271-F280.
20. VM Campese (1994) Salt sensitivity in hypertension. Renal and cardiovascular implications. Hypertension 23 531-550.
21. MH Weinberger, NS Fineberg, SE Fineberg and M Weinberger (2001) Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 37 429-432.
22. J Schnermann and J Briggs (1992) Function of the juxtaglomerular apparatus: local control of glomerular dynamics. DW Seldin, G Giebisch (Eds) The Kidney: Physiology and Pathophysiology 2nd ed. New York: Raven Press 1249-1290.
23. DE Hricik (1985) Captopril-induced renal insufficiency and the role of sodium balance. Ann Intern Med 103 222-223.
24. SC Textor, RC Tarazi, AC Novick, et al. (1984) Regulation of renal haemodynamics and glomerular filtration in patients with renovascular hypertension during converting enzyme inhibition with captopril. Am J Med 76 29-37.
25. JE Hall, AC Guyton and MW Brands (1995) Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin-angiotensin system. JH Laragh, BM Brenner (Eds) Hypertension: Pathophysiology, Diagnosis and Management 2nd ed. New York: Raven Press 1451-1475.
26. S Anderson, HG Rennke and BM Brenner (1986) Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Inv 77 1993-2000.
27. HH Parving, E Hommel and UM Smidt (1988) Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BM] 297 1086-1091.
28. EM Lewis, LG Hunsicker, RP Bain and ED Rohde (1993) The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Mea 329 1456-1462.
29. BM Brenner, ME Cooper, D de Zeeuw, et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl I Med 345 861-869.
30. M Matsuaka, J Hymes and I Ichikawa (1996) Angiotensin in progressive renal diseases: theory and practice. J Am Soc Nephrol 7 2025-2043.
31. M Ketteler, NA Noble and WA Border (1995) Transforming growth factor-B and angiotensin: the missing link from glomerular hyperfiltration to glomerulosclerosis? Ann Rev Physiol 57 279-295.
32. KA Griffin, I Abu-Amarah, M Picken and AK Bidani (2003) Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension 41 201-206.
33. E Eng, M Veniants, J Floege, et al. (1994) Renal proliferative and phenotypic changes in rats with two-kidney one-clip Goldblatt hypertension. Am I Hypertens 7 177-185.
34. JE Hall and JP Granger (2005) Regulation of fluid and electrolyte balance in hypertension: role of hormones and peptides. EJ Battegay, GHY Lip, GL Bakris (Eds) Hypertension: Principles and Practice Boca Raton, FL: Taylor & Francis 121-142.
35. PJ Harris and JA Young (1977) Dose-dependent stimulation and inhibition of proximal tubular sodium reabsorption by angiotensin II in the rat kidney. Pflugers Arch 367 295-297.
36. LG Navar, LM Harrison-Bernard, A Nishiyama and H Kobori (2002) Regulation of intrarenal angiotensin II in hypertension. Hypertension 39 316-322.
37. G Capasso, R Unwin, F Ciani, et al. (1994) Bicarbonate transport along the loop of Henle. II. Effects of acid-base, dietary and neurohumoral determinants. J Clin Invest 94 830-838.
38. H Amlal, C LeGoff, C Vernimmen, et al. (1998) ANG II controls Na +-K + (NH 4 +)-2Ch cotransport via 20-HETE and PKC in medullary thick ascending limb. Am I Physiol 274 C1047-C1056.
39. J Peti-Peterdi, DG Warnock and PD Bell (2002) Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT(1) receptors. J Am Soc Nephrol 13 1131-1135.
40. J Schnermann and DZ Levine (2003) Paracrine factors in tubuloglomerular feedback: adenosine, ATP, and nitric oxide. Annu Rev Physiol 65 501-529.
41. PJ Fuller and MJ Young (2005) Mechanisms of mineralocorticoid action. Hypertension 46 1227-1235.
42. JW Funder (2005) The nongenomic actions of aldosterone. Endocr Rev 26 313-321.
43. M Wehling, J Kasmayr and K Theisen (1991) Rapid effects of mineralocorticoids on sodium-proton exchanger: genomic or nongenomic pathway? Am J Physiol 260 E719-E726.
44. P Romagni, F Rossi, L Guerrini, et al. (2003) Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 166 345-349.
45. P Gunaruwan, M Schmitt, J Taylor, et al. (2002) Lack of rapid aldosterone effects on forearm resistance vasculature in health. J Renin Angiotensin Aldosterone Syst 3 123-125.
46. JE Hall, JP Granger, MJ Smith Jr and AJ Premen (1984) Role of renal hemodynamics and arterial pressure in aldosterone “escape.”. Hypertension 6(Suppl I), I183-I192.
47. DA Calhoun, MK Nishizaka, MA Zaman, et al. (2002) Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40 892-896.
48. H Krum, H Nolly, D Workman, et al. (2002) Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40 117-123.
49. R Rocha and CT Stier Jr (2001) Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 12 308-314.
50. RB de Paula, AA da Silva and JE Hall (2004) Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 43 41-47.
51. JE Hall (2003) The kidney, hypertension, and obesity. Hypertension 41 625-633.
52. GF DiBona (2003) Neural control of the kidney: past, present, and future. Hypertension 4 621-624.
53. PG Guyenet (2006) The sympathetic control of blood pressure. Nat Rev 7 335-346.
54. RAL Dampney, J Horiuchi, S Killinger, et al. (2005) Long-term regulation of arterial blood pressure by hypothalamic nuclei: some critical questions. Clin Exper Pharmacol Physiol 32 419-425.
55. S Kassab, T Kato, FC Wilkins, et al. (1995) Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 25 893-897.
56. TE Lohmeier, DA Hildebrandt, S Warren, et al. (2005) Recent insights into the interactions between the baroreflex and the kidneys in hypertension. Am I Physiol Regul Integr Comp Physiol 288 R828-R836.
57. M Esler (2000) The sympathetic system and hypertension. Am J Hypertens 13 99S-105S.
58. AW Cowley Jr (1992) Long-term control of arterial blood pressure. Physiol Rev 72 231-300.
59. C Orfila, C Damase-Michel, JC Lepert, et al. (1993) Renal morphological changes after sinoaortic denervation in dogs. Hypertension 21 758-766.
60. NM Kaplan (2002) Kaplan's Clinical Hypertension 8th ed. Philadelphia: Lippincott Williams & Wilkins
61. RJ Garrison, WB Kannel, J Stokes, et al. (1987) Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 16 234-251.
62. MR Wofford, DC Anderson, CA Brown, et al. (2001) Antihypertensive effect of alpha and beta adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 14 164-168.
63. JE Hall, DA Hildebrandt and JJ Kuo (2001) Obesity hypertension: role of leptin and sympathetic nervous system. Am I Hypertens 14 103s-115s.
64. EW Shek, MW Brands and JE Hall (1998) Chronic leptin infusion increases arterial pressure. Hypertension 31 409-414.
65. AL Mark, RA Shaffer, ML Correia, et al. (1999) Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow mice. J Hypertens 17 1949-1953.
66. M Ozata, IC Ozdemir and J Licinio (1999) Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 10 3686-3695.
67. AA daSilva, JJ Kuo and JE Hall (2004) Role of hypothalamic melanocortin 3/4 receptors in mediating the chronic cardiovascular, renal, and metabolic actions of leptin. Hypertension 43 1312-1317.
68. LS Tallam, AA da Silva and JE Hall (2006) Melanocortin-4 receptor mediates chronic cardiovascular and metabolic actions of leptin. Hypertension 48 58-64.
69. M Yanagisawa, H Kurihara, S Kimura, et al. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 411-415.
70. D Kohan (1997) Endothelins in the normal and diseased kidney. Am I Kidney Dis 29 2-26.
71. EL Schiffrin (1995) Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 25 1135-1143.
72. MS Simonson and MJ Dunn (1993) Endothelin peptides and the kidney. Annu Rev Physiol 55 249-265.
73. EL Schiffrin (2005) Vascular endothelin in hypertension. Vascul Pharmacol 43 19-29.
74. JP Granger (2003) Endothelin. Am J Physiol Regul Integr Comp Physiol 285 R298-R301.
75. DE Kohan (2006) The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure. Curr Opin Nephrol Hypertens 15 34-40.
76. S Kassab, J Novak, T Miller, et al. (1997) Role of endothelin in mediating the attenuated renal hemodynamics in Dahl salt-sensitive hypertension. Hypertension 30 682-686.
77. S Kassab, M Miller, J Novak, et al. (1998) Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertension 31 397-402.
78. BT Alexander, KL Cockrell, AN Rinewalt, et al. (2001) Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol 280 R1388-R1392.
79. JR Ballew and GD Fink (2001) Role of ET-1 A receptors in experimental ANG II-induced hypertension in rats. Am J Physiol Regul Integr Comp Physiol 281 R150-R154.
80. LV d'Uscio, P Moreau, S Shaw, et al. (1997) Effects of chronic ET-1 A -receptor blockade in angiotensin II-induced hypertension. Hypertension 29 435-441.
81. C Perez del Villar, CJ Garcia Alonso, CA Feldstein, et al. (2005) Role of endothelin in the pathogenesis of hypertension. May Clin Proc 80 84-96.
82. JM Sasser, JS Pollock and DM Pollock (2002) Renal endothelin in chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol 283 R243-R248.
83. JP Granger, BT Alexander, MT Llinas, et al. (2001) Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Hypertension 38 718-722.
84. RA Khalil and JP Granger (2002) Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models. Am J Physiol Regul Integr Comp Physiol 283 R29-R45.
85. FC Wilkins Jr, A Alberola, HL Mizelle, et al. (1995) Systemic hemodynamics and renal function during long-term pathophysiological increases in circulating endothelin. Am J Physiol Regul Integr Comp Physiol 268 R375-R381.
86. BT Alexander, AN Rinewalt, KL Cockrell, et al. (2001) Endothelin-A receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 37 485-489.
87. JP Granger, BBD LaMarca, K Cockrell, et al. (2006) Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol Med 122 383-392.
88. L Roberts, B LaMarca, L Fournier, et al. (2006) Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension 47 615-618.
89. BB LaMarca, WA Bennett, BT Alexander, et al. (2005) Hypertension produced by reductions in uterine perfusion in the pregnant rat. Role of tumor necrosis factor-α. Hypertension 46 1022-1025.
90. BB LaMarca, K Cockrell, E Sullivan, et al. (2005) Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 46 82-86.
91. R Dean, J Zhuo, D Alcorn, et al. (1996) Cellular localization of endothelin receptor subtypes in the rat kidney following in vitro labeling. Clin Exp Pharmacol Physiol 23 524-531.
92. CR Jones, CR Hiley, JT Pelton and RC Miller (1989) Autoradiographic localization of endothelin binding sites in kidney. Eur J Pharmacol 163 379-382.
93. FE Karet, RE Kuc and AP Davenport (1993) Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ET-1A and ET-1B in human kidney. Kidney Int 44 36-42.
94. P Nambi, M Pullen, HL Wu, et al. (1992) Identification of endothelin receptor subtypes in human renal cortex and medulla using subtype-selective ligands. Endocrinology 131 1081-1086.
95. CE Gariepy, DT Cass and M Yanagisawa (1996) Null mutation of endothelin-B receptor gene in spotting lethal rats causes aganglionic megacolon and white coat color. Proc Natl Acad Sci U S A 93 867-872.
96. FE Strachan, JC Spratt, IB Wilkinson, et al. (1999) Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 33 581-585.
97. CE Gariepy, T Ohuchi, SC Williams, et al. (2000) Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 105 925-933.
98. DM Pollock and JS Pollock (2001) Evidence for endothelin involvement in the response to high salt. Am J Physiol Renal Physiol 281 F144-F150.
99. AJ Bagnall, NF Kelland, F Gulliver-Sloan, et al. (2006) Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension 48 286-293.
100. Y Ge, A Bagnall, P Stricklett, K Strait, D Webb, Y Kotelevtsev, et al. (2006) Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol [Epub before print]
101. T Ohuchi, T Kuwaki, G Ling, et al. (1999) Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am J Physiol Regul Integr Comp Physiol 276 R1071-R1077.
102. M Kohzuki, CI Johnston, SY Chai, et al. (1989) Localization and endothelin receptors in the rat kidney. Eur J Pharmacol 160 193-194.
103. H Michel, A Backer, H Meyer-Lehnert, et al. (1993) Rat renal, aortic and pulmonary endothelin-1 receptors: effects of changes in sodium and water intake. Clin Sci (Colch) 85 593-597.
104. H Krum, RJ Viskoper, Y Lacourciere, M Budde and V Charlon (1998) The effect of an endothelin-receptor antagonist, bosentan, on blood pressure inpatients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 338 784-790.
105. CG Schnackenberg, K Kirchner, A Patel and JP Granger (1997) Nitric oxide, the kidney, and hypertension. Clin Exp Pharmacol Physiol 24 600-606.
106. PA Ortiz and JL Garvin (2002) Role of nitric oxide in the regulation of nephron transport. Am J Physiol Renal Physiol 282 F777-F784.
107. AW Cowley Jr, T Mori, D Mattson and AP Zou (2003) Role of renal NO production in the regulation of medullary blood flow. Am J Physiol Regul Integr Comp Physiol 284 R1355-R1369.
108. JP Granger and BT Alexander (2000) Abnormal pressure natriuresis in hypertension: role of nitric oxide. Acta Physiologica Scandinavia 168 161-168.
109. T Nakamura, A Alberola and JP Granger (1993) Role of renal interstitial pressure as a mediator of sodium retention during blockade of endothelium derived nitric oxide hypertension. Hypertension 21 956-960.
110. PW Sanders (2004) Sodium intake, endothelial cell signaling, and progression of kidney disease. Hypertension 43 142-146.
111. C Schnackenberg, B Tabor, M Strong and JP Granger (1997) Intrarenal NO blockade enhances renin secretion rate by a macula densa mechanism. Am J Physiol 272 R879-R886.
112. C Schnackenberg, C Wilkins and JP Granger (1995) Role of nitric oxide in modulating the vasoconstrictor actions of angiotensin II in preglomerular and postglomerular vessels in dogs. Hypertension 26 1024-1029.
113. JP Granger, A Alberola, F Salazer and T Nakamura (1992) Control of renal hemodynamics during intrarenal systemic EDNO synthesis blockade. J Cardiovasc Pharmacol 20 S160-S162.
114. JP Granger, J Novak, C Schnackenberg, S Williams and G Reinhart (1996) Role of renal nerves in mediating the hypertensive effects of nitric oxide synthesis inhibition. Hypertension 27 613-618.
115. FG Knox and JP Granger (1992) Control of sodium excretion: an integrative approach. E Windhager (Eds) Handbook of Renal Physiology New York: Oxford University Press 927-967.
116. DL Vesely (2001) Atrial natriuretic peptides in pathophysiological diseases. Cardiovasc Res 51 647-658.
117. JP Granger, TJ Opgenorth, J Salazar, JC Romero and JC Burnett Jr (1986) Long-term hypotensive and renal effects of chronic infusions of atrial natriuretic peptide in conscious dogs. Hypertension 8 II112-II116.
118. LG Melo, ME Steinhelper, SC Pang, Y Tse and U Ackermann (2000) ANP in regulation of arterial pressure and fluid-electrolyte balance: lessons from genetic mouse models. Physiol Genomics 3 45-58.
119. HF Cheng and RC Harris (2004) Cyclooxygenases, the kidney, and hypertension. Hypertension 43 525-530.
120. RJ Roman (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82 131-185.
121. CL Laffer, M Laniado-Schwartzman, MH Wang, A Nasjletti and F Elijovich (2003) Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic acid in human salt-sensitive versus salt-resistant hypertension. Circulation 107 574-578.
122. CL Laffer, M Laniado-Schwartzman, MH Wang, A Nasjletti and F Elijovich (2003) 20-HETE and furosemide-induced natriuresis in salt-sensitive essential hypertension. Hypertension 41 703-708.
123. Y Taniyama and KK Griendling (2003) Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42 1075-1081.
124. CS Wilcox (2002) Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 4 160-166.
125. RD Manning Jr, S Meng and N Tian (2003) Renal and vascular oxidative stress and salt-sensitivity of arterial pressure. Acta Physiol Scand 179 243-250.
126. JF Reckelhoff and JC Romero (2003) Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol 284 R893-R912.
127. JC Romero and JF Reckelhoff (1999) State-of-the-art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 34 943-949.
128. M Sedeek, BT Alexander, SR Abram and JP Granger (2003) Role of oxidative stress in endothelin-induced hypertension in rats. Hypertension 42 806-810.
129. JL Garvin and PA Ortiz (2003) The role of reactive oxygen species in the regulation of tubular function. Acta Physiol Scand 179 225-232.
130. CU Chae, RT Lee, N Rifai and PM Ridker (2001) Blood pressure and inflammation in apparently healthy men. Hypertension 38 399-403.
131. KP Conrad and DF Benyo (1997) Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 37 240-249.
132. MM Donners, MJ Daemen, KB Cleutjens and S Heeneman (2003) Inflammation and restenosis: implications for therapy. Ann Med 35 523-531.
133. N Sattar, DW McCarey, H Capell and IB McInnes (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108 2957-2963.
134. DA Siwik and WS Colucci (2004) Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 9 43-51.
135. ZH Zhang, SG Wei, J Francis and RB Felder (2003) Cardiovascular and renal sympathetic activation by blood-borne TNF in rat: the role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol 284 R916-R927.
136. Y Han, MS Runge and AR Braiser (1999) Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 84 695-703.
137. M Ruiz-Ortega, M Ruperez, O Lorenzo, V Esteban, J Blanco, S Mezzano and J Egido (2002) Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int 82 12-22.
138. D Sanz-Rosa, MP Oubina, E Cediel, N De Las Heras, O Vegazo, J Jimenez, et al. (2005) Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: Role of NFKB/IKB system. Am J Physiol Heart Circ Physiol 288 H111-H115.
139. JP Granger, BT Alexander, MT Llinas, WA Bennett and RA Khalil (2002) Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation 9 147-160.
140. JB Giardina, GM Green, KL Cockrell, JP Granger and RA Khalil (2002) TNF enhances contraction and inhibits endothelial NO-cGMP relaxation in systemic vessels of pregnant rats. Am J Physiol Regul Integr Comp 283 R130-R143.
141. BT Alexander, MB Massey, KL Cockrell, WA Bennett and JP Granger (2002) Elevations in plasma TNF in pregnant rats decreases renal nNOS and iNOS and results in hypertension. Am J Hypertens 15 170-175.
142. JM Orshal and RA Khalil (2004) Reduced endothelial NO-cGMP-mediated vascular relaxation and hypertension in IL-6-infused pregnant rats. Hypertension 43 434-444.
143. DL Lee, LC Sturgis, H Labazi, JB Osborne Jr, C Fleming, JS Pollock, et al. (2006) Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol 290 H935-H940.